



(51) International Patent Classification:

A61K 35/48 (2006.01) A61L 27/52 (2006.01)
A61K 38/18 (2006.01) A61P 19/00 (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:

PCT/US2012/038407

(22) International Filing Date:

17 May 2012 (17.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13/111,933 19 May 2011 (19.05.2011) US

(71) Applicant (for all designated States except US): **ADVANCED TECHNOLOGIES AND REGENERATIVE**

MEDICINE, LLC [US/US]; 325 Paramount Drive, Raynham, Massachusetts 02767 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KRAMER, Brian C.** [US/US]; 205 Pemberton Avenue, Plainfield, New Jersey 07060 (US). **BROWN, Laura J.** [US/US]; 76 Peter Raftery Drive, Hamilton Square, New Jersey 08690 (US). **KIHM, Anthony J.** [US/US]; 7 Harrogate Circle, Princeton, New Jersey 08540 (US).


(74) Agents: **HERBERT, Toni-Junell** et al.; Venable LLP, P.O. Box 34385, Washington, District of Columbia 20043-9998 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,


[Continued on next page]

(54) Title: TREATMENT OF INTERVERTEBRAL DISC DEGENERATION USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS

A.



B.



C.




Figure 1

(57) Abstract: Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells and a hydrogel. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.



DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))